

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
HIV/AIDS	HIV gp120	<p><i>In vitro</i> studies suggest gp120 immunogens from patients that produce broadly neutralizing HIV antibodies could help develop prophylactic vaccines. Four gp120 immunogens based on peptide sequences from the patients' circulating HIV isolates bound to a variety of known broadly neutralizing HIV antibodies. Against a panel of diverse HIV isolates, serum from rabbits vaccinated with two of the four immunogens plus an adjuvant had broad but weak neutralizing activity. Next steps could include testing the vaccine strategy in animal models and improving potency.</p> <p><b>SciBX 7(9); doi:10.1038/scibx.2014.261</b>  <b>Published online March 6, 2014</b></p>	Patent and licensing status unavailable	<p>Carbonetti, S. <i>et al. PLoS One</i>; published online Jan. 23, 2014; doi:10.1371/journal.pone.0086905  <b>Contact:</b> D. Noah Sather, Seattle BioMed, Seattle, Wash.                      e-mail: <a href="mailto:noah.sather@seattlebiomed.org">noah.sather@seattlebiomed.org</a></p>